Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)

Previous study showed that the proportions of hemorrhagic Infarction after intravenous thrombolysis were 24.2% and 32.5% in the control group and the alteplase group, and most of them were asymptomatic. Hemorrhagic Infarction was a part of the natural progression after acute ischemic stroke. Previous study have shown no significant relationship between hemorrhagic Infarction and poor outcome in acute ischemic stroke (AIS) patients. In this study, a randomized controlled trial will be conducted to explore the efficacy and safety of early antiplatelet therapy after hemorrhagic infarction in acute ischemic stroke treated with intravenous thrombolysis.

NCT Number	NCT04624295
Lead Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University Collaborators: Shaoxing People's Hospital, Affiliated Hospital of Jiaxing University, Huzhou Central Hospital, The Second Affiliated Hospital of Jiaxing University, Jinhua Central Hospital, Taizhou Hospital, Ningbo Medical Center Lihuili Hospital, Ningbo No.2 Hospital, Lishui Country People's Hospital, Wenzhou Central Hospital, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Shenzhen Second People's Hospital, The Affiliated Hospital of Xuzhou Medical University
Conditions	Antiplatelet Therapy, Hemorrhagic Infarction
Enrollment	294 participants
Start Date	2021-01-01
Primary Completion	2025-12-31 (estimated)
Study Completion	2026-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-06-15